Literature DB >> 22127222

Heidelberg spectral-domain optical coherence tomographic findings in retinal artery macroaneurysm.

Dafna Goldenberg1, Uri Soiberman, Anat Loewenstein, Michaella Goldstein.   

Abstract

PURPOSE: To describe the morphologic variables of macroaneurysms, to assess their diameter in comparison to their upstream/downstream vessel diameter as visualized on spectral-domain optical coherence tomography, and to describe morphologic changes in the retina adjacent to macroaneurysm.
METHODS: A retrospective case series of adult patients who were clinically diagnosed with retinal macroaneurysms and who underwent Heidelberg spectral-domain optical coherence tomography (OCT) between June 2009 and October 2010.
RESULTS: A total of 12 patients (age range, 31-95 years, 2 men) in whom macroaneurysms were demonstrated by spectral-domain OCT (12 eyes). All the macroaneurysms had a typical OCT appearance, and a diameter of 285.33 ± 76.98 μm. The diameter of the upstream/downstream vessel was 117.5 ± 17.13 μm (P = 0.0001 vs. the mean macroaneurysm diameter). Other related OCT findings were superficial retinal hemorrhage, intraretinal lipids, and intraretinal edema prominently involving the outer retinal layers.
CONCLUSION: Spectral-domain OCT is an effective tool for detecting retinal macroaneurysms. It also provides important supplementary clinical information that may be helpful in planning the management of macroaneurysm, without the need for ancillary tests.

Entities:  

Mesh:

Year:  2012        PMID: 22127222     DOI: 10.1097/IAE.0b013e318229b233

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  11 in total

1.  The influence of axial length on confocal scanning laser ophthalmoscopy and spectral-domain optical coherence tomography size measurements: a pilot study.

Authors:  T Röck; B Wilhelm; K U Bartz-Schmidt; D Röck
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-23       Impact factor: 3.117

2.  Automated vessel diameter quantification and vessel tracing for OCT angiography.

Authors:  Wei Wei; Qinqin Zhang; Samuel G Rayner; Wan Qin; Yuxuan Cheng; Fupeng Wang; Ying Zheng; Ruikang K Wang
Journal:  J Biophotonics       Date:  2020-09-24       Impact factor: 3.207

Review 3.  Ruptured retinal arterial macroaneurysm: diagnosis and management.

Authors:  Ashley M Speilburg; Stephanie A Klemencic
Journal:  J Optom       Date:  2013-09-26

4.  Foveal Exudative Macroaneurysm Treated with Intravitreal Ranibizumab.

Authors:  Carlos Menezes; Rui Carvalho; Carla Teixeira; José Alberto Lemos; Rita Gonçalves; Pedro Coelho; André Lima
Journal:  Case Rep Ophthalmol       Date:  2015-06-02

5.  Noninvasive vascular imaging of ruptured retinal arterial macroaneurysms by Doppler optical coherence tomography.

Authors:  Masahiro Miura; Daisuke Muramatsu; Young-Joo Hong; Yoshiaki Yasuno; Ayako Itami; Takuya Iwasaki; Hiroshi Goto
Journal:  BMC Ophthalmol       Date:  2015-07-22       Impact factor: 2.209

6.  Arterial macroaneurysm of the optic disc.

Authors:  Cem Ozgonul; Cagri Giray Besirli
Journal:  Am J Ophthalmol Case Rep       Date:  2018-04-05

7.  Optic nerve head retinal artery macroaneurysm: Report of a case.

Authors:  Ramesh Venkatesh; Prachi Gurav
Journal:  SAGE Open Med Case Rep       Date:  2019-08-08

8.  Quantifying optical microangiography images obtained from a spectral domain optical coherence tomography system.

Authors:  Roberto Reif; Jia Qin; Lin An; Zhongwei Zhi; Suzan Dziennis; Ruikang Wang
Journal:  Int J Biomed Imaging       Date:  2012-06-26

9.  Optical coherence tomography (OCT) angiography findings in retinal arterial macroaneurysms.

Authors:  Maged Alnawaiseh; Friederike Schubert; Pieter Nelis; Gabriele Wirths; André Rosentreter; Nicole Eter
Journal:  BMC Ophthalmol       Date:  2016-07-22       Impact factor: 2.209

10.  Retinal racemose hemangioma with retinal artery macroaneurysm: Optical coherence tomography angiography (OCTA) findings.

Authors:  Raval Vishal; Oli Avadesh; Rao Srinivas; Das Taraprasad
Journal:  Am J Ophthalmol Case Rep       Date:  2018-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.